In Seagen Inc. v. Daiichi Sankyo Company Ltd., the Federal Circuit reversed a jury verdict and held asserted claims of Seagen’s patent covering antibody‑drug conjugates invalid for lack of sufficient written description and enablement under 35 U.S.C. §112(a). The court focused on whether the specification supported the claimed linker and drug moiety structures, concluding it did not.
